» Articles » PMID: 9234681

C/EBP Factor Suppression of Inhibition of Type II Secreted Phospholipase A2 Promoter in HepG2 Cells: Possible Role of Single-strand Binding Proteins

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1997 Aug 1
PMID 9234681
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that the type II secreted phospholipase A2 (sPLA2) promoter from positions (-326 to +20) ([-326;+20] promoter) is negatively regulated by two adjacent regulatory elements, C (-210 to -176) and D (-247 to -210). This study examines in greater detail the way in which this negative regulation operates. Successive 5' deletions of the [-326;+20] type II sPLA2 promoter indicated that the region upstream of position -195 inhibits the transcription activity sixfold in HepG2 cells but not in HeLa cells. Although the whole [-326;-176] region decreased the activity of a heterologous thymidine kinase promoter, this effect was orientation and position sensitive. C/EBP beta, C/EBP alpha, and C/EBP delta, which bind to element C, prevented the inhibition of promoter activity. Electrophoretic mobility shift experiments identified the binding of NF1-like proteins to the [-225;-218] site, which overlaps an insulin response-like sequence, 5'-TGTTTTG-3'. This sequence bound a factor which also recognized the promoters of the apolipoproteins C-III and A-II. Substitutions preventing the binding of this factor or the NF1-like proteins did not increase the transcription activity, but substitution in the [-217;-204] sequence blocked the transcription inhibition. This sequence did not bind any double-strand binding factor, but its antisense strand is critical for the binding of single-strand binding proteins to the [-232;-191] region. We therefore suggest that these single-strand binding proteins are involved in the inhibitory mechanism.

Citing Articles

Transcriptional Regulation of the Group IIA Secretory Phospholipase A2 Gene by C/EBP in Rat liver and its Relationship to Hepatic Gluconeogenesis during Sepsis.

Yang R, Hsu C, Lee T, Kuo K, Wu S, Chen Y Emerg Med (Los Angel). 2014; 3:151.

PMID: 25035816 PMC: 4098070. DOI: 10.4172/2165-7548.1000151.


Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease.

Quach N, Arnold R, Cummings B Biochem Pharmacol. 2014; 90(4):338-48.

PMID: 24907600 PMC: 4104246. DOI: 10.1016/j.bcp.2014.05.022.


Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Sharma P, Thakran S, Deng X, Elam M, Park E J Biol Chem. 2013; 288(23):16321-16333.

PMID: 23629656 PMC: 3675570. DOI: 10.1074/jbc.M112.445569.


Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.

Exeter H, Folkersen L, Palmen J, Franco-Cereceda A, Cooper J, Kalea A PLoS One. 2012; 7(7):e41139.

PMID: 22879865 PMC: 3412631. DOI: 10.1371/journal.pone.0041139.


New developments in phospholipase A2.

Chaminade B, le Balle F, Fourcade O, Nauze M, Delagebeaudeuf C, Gassama-Diagne A Lipids. 1999; 34 Suppl:S49-55.

PMID: 10419088 DOI: 10.1007/BF02562228.

References
1.
Lu S, Rodriguez M, Liao W . YY1 represses rat serum amyloid A1 gene transcription and is antagonized by NF-kappa B during acute-phase response. Mol Cell Biol. 1994; 14(9):6253-63. PMC: 359152. DOI: 10.1128/mcb.14.9.6253-6263.1994. View

2.
Pei D, Shih C . Transcriptional activation and repression by cellular DNA-binding protein C/EBP. J Virol. 1990; 64(4):1517-22. PMC: 249285. DOI: 10.1128/JVI.64.4.1517-1522.1990. View

3.
Cardot P, Pastier D, Lacorte J, Mangeney M, Zannis V, Chambaz J . Purification and characterization of nuclear factors binding to the negative regulatory element D of human apolipoprotein A-II promoter: a negative regulatory effect is reversed by GABP, an Ets-related protein. Biochemistry. 1994; 33(40):12139-48. DOI: 10.1021/bi00206a017. View

4.
Tanuma Y, Nakabayashi H, Esumi M, Endo H . A silencer element for the lipoprotein lipase gene promoter and cognate double- and single-stranded DNA-binding proteins. Mol Cell Biol. 1995; 15(1):517-23. PMC: 232003. DOI: 10.1128/MCB.15.1.517. View

5.
Desbois C, Masse T, Madjar J . Optimization of the CAT assay procedure by determining the initial rate of the enzymatic reaction. Trends Genet. 1992; 8(9):300-1. DOI: 10.1016/0168-9525(92)90260-b. View